New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer
Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the CIBERONC cancer research network. The study, published in Cell Reports Medicine, highlights the role of HGF (hepatocyte growth factor)—which is linked to cell proliferation and survival—in the poor prognosis of this disease and its resistance to treatment. The research explores a novel approach that adds a MET inhibitor to standard therapy and demonstrates improved treatment response.
Small cell lung cancer is one of the most aggressive ...